In the β-amyloid-induced AD mice model, activation of GPR55 using the commercial agonist O-1602 ameliorated the induced cognitive impairment in behavioral tests by suppressing the RhoA/ROCK2 pathway and decreasing β-amyloid levels in the hippocampus and frontal cortex. This evidence concerns the gene GPR55 and Alzheimer disease.